Eli Lilly | LLY - Sales Revenues

Stock Price
868.45
Daily Change
-15.51 -1.75%
Monthly
-2.05%
Yearly
-1.01%
Q2 Forecast
865.04

Eli Lilly reported $19.3B in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
AbbVie USD 16.62B 840M Dec/2025
Abbott USD 11.16B 300M Mar/2026
ALKERMES USD 384.5M 9.7M Dec/2025
Amgen USD 9.9B 340M Dec/2025
AstraZeneca USD 15.5B 313M Dec/2025
Baxter International USD 2.97B 130M Dec/2025
Biogen USD 2.28B 250M Dec/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Coherus Biosciences USD 12.75M 1.18M Dec/2025
Drreddys Laboratories INR 87.27B 1.82B Dec/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
Gilead Sciences USD 7.93B 130M Dec/2025
GlaxoSmithKline GBP 8.62B 73M Dec/2025
Glaxosmithkline GBP 11.46B 59.16M Dec/2025
J&J USD 24.1B 500M Mar/2026
Medtronic USD 9B 39M Jan/2026
Merck USD 16.4B 880M Dec/2025
Neurocrine Biosciences USD 805.5M 10.6M Dec/2025
Novartis USD 13.86B 50M Dec/2025
Novartis USD 13.86B 498M Dec/2025
Novo Nordisk DKK 79.14B 4.16B Dec/2025
Perrigo USD 1.11B 70M Dec/2025
Pfizer USD 17.58B 880M Dec/2025
Phibro Animal Health USD 373.91M 10.02M Dec/2025
Prestige Brands USD 283.44M 9.34M Dec/2025
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Roche Holding CHF 15.65B 274.5M Dec/2025
Sanofi EUR 11.24B 60M Mar/2026
Sanofi EUR 12.14B 65M Mar/2026
United Therapeutics USD 790.2M 9.3M Dec/2025
Zoetis USD 2.4B 0 Dec/2025